(5R,6S)-6-[(1R)-1-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]ethyl]-7-oxo-3-[(2R)-tetrahydro-2-furanyl]-4-thia-1-azabicyclo[3.2.0]hept-2 -ene-2-carboxylic acid 2-propenyl ester , Faropenem intermediate

CAS : 120705-67-1

Ref. 3D-VEA70567

Informations sur le produit

• Nom: (5R,6S)-6-[(1R)-1-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]ethyl]-7-oxo-3-[(2R)-tetrahydro-2-furanyl]-4-thia-1-azabicyclo[3.2.0]hept-2 -ene-2-carboxylic acid 2-propenyl ester , Faropenem intermediate
• Synonymes: 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid,6-[1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-7-oxo-3-(tetrahydro-2-furanyl)-,2-propenylester,[5R-[3(R*),5a,6a(R*)]], prop-2-en-1-yl (5R,6S)-6-[(1R)-1-{[tert-butyl(dimethyl)silyl]oxy}ethyl]-7-oxo-3-(tetrahydrofuran-2-yl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate, Ally(1'R,2''R,5R,6S)-6(1'-tert-butyl dimethyl silyloxyethy)-2-(2''-tetrahydrofuranyl)penem-3-carboxylate, Faropenem Intermediate, 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-7-oxo-3-(tetrahydro-2-furanyl)-, 2-propenyl ester, [5R-[3(R*),5a,6a(R*)]]-, Faropenem Sodium Intermediate, (5R,6S)-6-[(R)-1-(Tert-Butyl-Dimethyl-Silanyloxy)-Ethyl]-7-Oxo-3-(R)-Tetrahydro-Furan-2-Yl-4-Thia-1-Aza-Bicyclo[3.2.0]Hept-2-Ene-2-Carboxylic Acid Allyl Ester, Farom, Ally(1'R,2''R,5R,6S)-6(1'-tert-butyl dimethyl silyoxyethy)-2-(2''-tetrahydrofuranyl)penem-3-carboxylate

Description

Faropenem is a prodrug of the antibiotic daloxate. It is synthesized by condensing 6-(1-hydroxyethyl)-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thiaazabicyclo[3.2.0]heptane-2-carboxylic acid 2-(propenyl ester) with (1S,5R,6S)-6-[(1R)-1-[[(1,1 -dimethylethyl)dimethylsilyl]oxy]ethyl]-7-oxo-3-[(2R)-tetrahydrofuran--2-yl]-4 -thiaazabicyclo[3.2.0]heptane -2-(propenyl ester). The reaction is carried out in the presence of a phase transfer catalyst and an inorganic salt to produce a mixture

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 439.64 g/mol
• Formule: C₂₁H₃₃NO₅SSi
• Degré de pureté: Min. 95%